ERBB2 and breast carcinoma: Trastuzumab is the first monoclonal antibody to be approved for a solid carcinoma, which targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2/ErbB2) in breast cancer and other solid tumors (Cruz and Kayser, 2019).